Consequently, the investigation of the targeting KIR2DL4 therapy has garnered significant attention in the realm of research, as it presents promising opportunities for the advancement of novel immunotherapeutic approaches aimed at bolstering anti-tumor immune responses. The gene discussed is KIR2DL4; the disease is neoplasm.